LY2140023 + ammonium chloride

LY2140023 + ammonium chloride is a **combination product** consisting of LY2140023 (pomaglumetad methionil) and ammonium chloride. LY2140023 is a methionine amide prodrug developed by Eli Lilly and Company for the treatment of schizophrenia and related psychotic disorders. After oral administration, LY2140023 is hydrolyzed to pomaglumetad (LY404039), a highly selective and potent **agonist of group II metabotropic glutamate receptors (mGluR2 and mGluR3)**, which may modulate glutamatergic neurotransmission and offer antipsychotic effects distinct from traditional dopaminergic agents. The combination with ammonium chloride is not a standard clinical formulation and is not described in key clinical, pharmacological, or regulatory documentation; ammonium chloride itself is an acidifying agent sometimes used for urinary acidification or as an expectorant, but its rationale in combination with LY2140023 is unestablished in the literature.

Other names

pomaglumetad methionil + ammonium chloride